{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:20:15Z","timestamp":1785162015976,"version":"3.55.0"},"publisher-location":"Cham","reference-count":112,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030573775","type":"print"},{"value":"9783030573782","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/164_2020_354","type":"book-chapter","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T08:05:39Z","timestamp":1585555539000},"page":"423-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy"],"prefix":"10.1007","author":[{"given":"Sabashini K.","family":"Ramchand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ego","family":"Seeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"354_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, San Martin J, Munoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87\u201394. https:\/\/doi.org\/10.1007\/s00198-007-0485-y","journal-title":"Osteoporos Int"},{"key":"354_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1359\/jbmr.2003.18.6.1012","volume":"18","author":"O Akkus","year":"2003","unstructured":"Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB (2003) Aging of microstructural compartments in human compact bone. J Bone Miner Res 18:1012\u20131019. https:\/\/doi.org\/10.1359\/jbmr.2003.18.6.1012","journal-title":"J Bone Miner Res"},{"key":"354_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00198-007-0533-7","volume":"19","author":"MR Allen","year":"2008","unstructured":"Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD (2008) Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 19:329\u2013337. https:\/\/doi.org\/10.1007\/s00198-007-0533-7","journal-title":"Osteoporos Int"},{"key":"354_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00223-009-9315-x","volume":"86","author":"MR Allen","year":"2010","unstructured":"Allen MR, Erickson AM, Wang X, Burr DB, Martin RB, Hazelwood SJ (2010) Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int 86:67\u201371. https:\/\/doi.org\/10.1007\/s00223-009-9315-x","journal-title":"Calcif Tissue Int"},{"key":"354_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N, van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, van den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537\u2013543. https:\/\/doi.org\/10.1093\/hmg\/10.5.537","journal-title":"Hum Mol Genet"},{"key":"354_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans W, Patel N, Ebeling M, van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, van Hul W (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39:91\u201397. https:\/\/doi.org\/10.1136\/jmg.39.2.91","journal-title":"J Med Genet"},{"key":"354_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11914-008-0005-9","volume":"6","author":"JP Bilezikian","year":"2008","unstructured":"Bilezikian JP (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24\u201330. https:\/\/doi.org\/10.1007\/s11914-008-0005-9","journal-title":"Curr Osteoporos Rep"},{"key":"354_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.bone.2011.08.009","volume":"49","author":"A Bjornerem","year":"2011","unstructured":"Bjornerem A, Ghasem-Zadeh A, Bui M, Wang X, Rantzau C, Nguyen TV, Hopper JL, Zebaze R, Seeman E (2011) Remodeling markers are associated with larger intracortical surface area but smaller trabecular surface area: a twin study. Bone 49:1125\u20131130. https:\/\/doi.org\/10.1016\/j.bone.2011.08.009","journal-title":"Bone"},{"key":"354_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jbmr.3333","volume":"33","author":"A Bjornerem","year":"2018","unstructured":"Bjornerem A, Wang X, Bui M, Ghasem-Zadeh A, Hopper JL, Zebaze R, Seeman E (2018) Menopause-related appendicular bone loss is mainly cortical and results in increased cortical porosity. J Bone Miner Res 33:598\u2013605. https:\/\/doi.org\/10.1002\/jbmr.3333","journal-title":"J Bone Miner Res"},{"key":"354_CR10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, Pa THSI (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215. https:\/\/doi.org\/10.1056\/NEJMoa031975","journal-title":"N Engl J Med"},{"key":"354_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"354_CR13","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949\u20132957. https:\/\/doi.org\/10.1210\/jc.2018-00163","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, Investigators E (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860. https:\/\/doi.org\/10.1210\/jc.2007-0711","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM, Project FBQ (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642. https:\/\/doi.org\/10.1002\/jbmr.3641","journal-title":"J Bone Miner Res"},{"key":"354_CR16","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","volume":"34","author":"P Chavassieux","year":"2019","unstructured":"Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A (2019) Bone-forming and antiresorptive effects of Romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34:1597\u20131608. https:\/\/doi.org\/10.1002\/jbmr.3735","journal-title":"J Bone Miner Res"},{"key":"354_CR17","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1359\/JBMR.050105","volume":"20","author":"P Chen","year":"2005","unstructured":"Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962\u2013970. https:\/\/doi.org\/10.1359\/JBMR.050105","journal-title":"J Bone Miner Res"},{"key":"354_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","volume":"16","author":"F Cosman","year":"2001","unstructured":"Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925\u2013931. https:\/\/doi.org\/10.1359\/jbmr.2001.16.5.925","journal-title":"J Bone Miner Res"},{"key":"354_CR19","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772\u20133780. https:\/\/doi.org\/10.1210\/jc.2008-2719","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503\u2013511. https:\/\/doi.org\/10.1002\/jbmr.238","journal-title":"J Bone Miner Res"},{"key":"354_CR21","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/jbmr.1853","volume":"28","author":"F Cosman","year":"2013","unstructured":"Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH (2013) Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 28:1328\u20131336. https:\/\/doi.org\/10.1002\/jbmr.1853","journal-title":"J Bone Miner Res"},{"key":"354_CR22","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"354_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198\u2013202. https:\/\/doi.org\/10.1002\/jbmr.3051","journal-title":"J Bone Miner Res"},{"key":"354_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/8756-3282(95)00113-r","volume":"16","author":"PD Delmas","year":"1995","unstructured":"Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603\u2013610. https:\/\/doi.org\/10.1016\/8756-3282(95)00113-r","journal-title":"Bone"},{"key":"354_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/8756-3282(95)80027-N","volume":"16","author":"DW Dempster","year":"1995","unstructured":"Dempster DW, Birchman R, Xu R, Lindsay R, Shen V (1995) Temporal changes in cancellous bone structure of rats immediately after ovariectomy. Bone 16:157\u2013161","journal-title":"Bone"},{"key":"354_CR26","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1210\/jc.2017-02669","volume":"103","author":"DW Dempster","year":"2018","unstructured":"Dempster DW, Brown JP, Fahrleitner-Pammer A, Kendler D, Rizzo S, Valter I, Wagman RB, Yin X, Yue SV, Boivin G (2018) Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2498\u20132509. https:\/\/doi.org\/10.1210\/jc.2017-02669","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gluer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726\u2013736. https:\/\/doi.org\/10.1359\/jbmr.081215","journal-title":"J Bone Miner Res"},{"key":"354_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00198-018-04819-1","volume":"30","author":"R Eastell","year":"2019","unstructured":"Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM (2019) Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int 30:667\u2013673. https:\/\/doi.org\/10.1007\/s00198-018-04819-1","journal-title":"Osteoporos Int"},{"key":"354_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s8756-3282(98)00072-6","volume":"23","author":"C Ejersted","year":"1998","unstructured":"Ejersted C, Oxlund H, Eriksen EF, Andreassen TT (1998) Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone 23:43\u201352. https:\/\/doi.org\/10.1016\/s8756-3282(98)00072-6","journal-title":"Bone"},{"key":"354_CR30","unstructured":"EMA (2018) Eladynos (Abaloparatide) Assessment Report \u2013 EMA\/CHMP\/581111\/2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/eladynos-epar-refusal-public-assessment-report_en.pdf"},{"key":"354_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bone.2016.05.004","volume":"89","author":"A Fahrleitner-Pammer","year":"2016","unstructured":"Fahrleitner-Pammer A, Burr D, Dobnig H, Stepan JJ, Petto H, Li J, Krege JH, Pavo I (2016) Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment. Bone 89:16\u201324. https:\/\/doi.org\/10.1016\/j.bone.2016.05.004","journal-title":"Bone"},{"key":"354_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.cmet.2017.01.001","volume":"25","author":"Y Fan","year":"2017","unstructured":"Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V, Figueroa CA, Kir S, Zhou X, Mannstadt M, Baron R, Bronson RT, Horowitz MC, Wu JY, Bilezikian JP, Dempster DW, Rosen CJ, Lanske B (2017) Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab 25:661\u2013672. https:\/\/doi.org\/10.1016\/j.cmet.2017.01.001","journal-title":"Cell Metab"},{"key":"354_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nmat1428","volume":"4","author":"GE Fantner","year":"2005","unstructured":"Fantner GE, Hassenkam T, Kindt JH, Weaver JC, Birkedal H, Pechenik L, Cutroni JA, Cidade GA, Stucky GD, Morse DE, Hansma PK (2005) Sacrificial bonds and hidden length dissipate energy as mineralized fibrils separate during bone fracture. Nat Mater 4:612\u2013616. https:\/\/doi.org\/10.1038\/nmat1428","journal-title":"Nat Mater"},{"key":"354_CR34","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa035725","journal-title":"N Engl J Med"},{"key":"354_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11505","volume":"7","author":"M Florio","year":"2016","unstructured":"Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, Zhang L, Han CY, Case R, Duguay AN, Grisanti M, Stevens J, Pretorius JK, Pacheco E, Jones H, Chen Q, Soriano BD, Wen J, Heron B, Jacobsen FW, Brisan E, Richards WG, Ke HZ, Ominsky MS (2016) A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun 7:11505. https:\/\/doi.org\/10.1038\/ncomms11505","journal-title":"Nat Commun"},{"key":"354_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.bone.2011.05.009","volume":"49","author":"RK Fuchs","year":"2011","unstructured":"Fuchs RK, Faillace ME, Allen MR, Phipps RJ, Miller LM, Burr DB (2011) Bisphosphonates do not alter the rate of secondary mineralization. Bone 49:701\u2013705. https:\/\/doi.org\/10.1016\/j.bone.2011.05.009","journal-title":"Bone"},{"key":"354_CR37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/jbmr.3384","volume":"33","author":"P Geusens","year":"2018","unstructured":"Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CA, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, Lopez-Romero P, Fahrleitner-Pammer A (2018) Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res 33:783\u2013794. https:\/\/doi.org\/10.1002\/jbmr.3384","journal-title":"J Bone Miner Res"},{"key":"354_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study G (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326\u2013339. https:\/\/doi.org\/10.7326\/0003-4819-146-5-200703060-00005","journal-title":"Ann Intern Med"},{"key":"354_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141\u2013149. https:\/\/doi.org\/10.1210\/en.2015-1726","journal-title":"Endocrinology"},{"key":"354_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/206489a0","volume":"206","author":"R Hattner","year":"1965","unstructured":"Hattner R, Epker BN, Frost HM (1965) Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206:489\u2013490","journal-title":"Nature"},{"key":"354_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bone.2017.11.003","volume":"107","author":"G Holdsworth","year":"2018","unstructured":"Holdsworth G, Greenslade K, Jose J, Stencel Z, Kirby H, Moore A, Ke HZ, Robinson MK (2018) Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists. Bone 107:93\u2013103. https:\/\/doi.org\/10.1016\/j.bone.2017.11.003","journal-title":"Bone"},{"key":"354_CR42","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932\u20131941. https:\/\/doi.org\/10.1359\/jbmr.2003.18.11.1932","journal-title":"J Bone Miner Res"},{"key":"354_CR43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747\u2013783. https:\/\/doi.org\/10.1210\/er.2011-1060","journal-title":"Endocr Rev"},{"key":"354_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/s0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, M\u00f6ricke R, L\u00f3pez-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240. https:\/\/doi.org\/10.1016\/s0140-6736(17)32137-2","journal-title":"Lancet"},{"key":"354_CR45","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMe038143","volume":"349","author":"S Khosla","year":"2003","unstructured":"Khosla S (2003) Parathyroid hormone plus alendronate--a combination that does not add up. N Engl J Med 349:1277\u20131279. https:\/\/doi.org\/10.1056\/NEJMe038143","journal-title":"N Engl J Med"},{"key":"354_CR46","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/jbmr.1665","volume":"27","author":"SW Kim","year":"2012","unstructured":"Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, Baek WY, Kim JE, Kronenberg HM (2012) Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 27:2075\u20132084. https:\/\/doi.org\/10.1002\/jbmr.1665","journal-title":"J Bone Miner Res"},{"key":"354_CR47","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/endo.132.4.8462456","volume":"132","author":"DB Kimmel","year":"1993","unstructured":"Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR (1993) The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577\u20131584. https:\/\/doi.org\/10.1210\/endo.132.4.8462456","journal-title":"Endocrinology"},{"key":"354_CR48","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","volume":"142","author":"PJ Kostenuik","year":"2001","unstructured":"Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR (2001) OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295\u20134304. https:\/\/doi.org\/10.1210\/endo.142.10.8437","journal-title":"Endocrinology"},{"key":"354_CR49","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"key":"354_CR50","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1359\/JBMR.051109","volume":"21","author":"R Lindsay","year":"2006","unstructured":"Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366\u2013373. https:\/\/doi.org\/10.1359\/JBMR.051109","journal-title":"J Bone Miner Res"},{"key":"354_CR51","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1359\/jbmr.070104","volume":"22","author":"R Lindsay","year":"2007","unstructured":"Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495\u2013502. https:\/\/doi.org\/10.1359\/jbmr.070104","journal-title":"J Bone Miner Res"},{"key":"354_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF02013227","volume":"26","author":"P Lips","year":"1978","unstructured":"Lips P, Courpron P, Meunier PJ (1978) Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26:13\u201317","journal-title":"Calcif Tissue Res"},{"key":"354_CR53","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/jbmr.5650050911","volume":"5","author":"CC Liu","year":"1990","unstructured":"Liu CC, Kalu DN (1990) Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res 5:973\u2013982. https:\/\/doi.org\/10.1002\/jbmr.5650050911","journal-title":"J Bone Miner Res"},{"key":"354_CR54","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1073\/pnas.1704460114","volume":"114","author":"AA Lloyd","year":"2017","unstructured":"Lloyd AA, Gludovatz B, Riedel C, Luengo EA, Saiyed R, Marty E, Lorich DG, Lane JM, Ritchie RO, Busse B, Donnelly E (2017) Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A 114:8722\u20138727. https:\/\/doi.org\/10.1073\/pnas.1704460114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"354_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1359\/jbmr.060314","volume":"21","author":"YL Ma","year":"2006","unstructured":"Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855\u2013864. https:\/\/doi.org\/10.1359\/jbmr.060314","journal-title":"J Bone Miner Res"},{"key":"354_CR56","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1210\/en.2010-1112","volume":"152","author":"YL Ma","year":"2011","unstructured":"Ma YL, Zeng QQ, Porras LL, Harvey A, Moore TL, Shelbourn TL, Dalsky GP, Wronski TJ, Aguirre JI, Bryant HU, Sato M (2011) Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology 152:1767\u20131778. https:\/\/doi.org\/10.1210\/en.2010-1112","journal-title":"Endocrinology"},{"key":"354_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","volume":"59","author":"YL Ma","year":"2014","unstructured":"Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalska D, Marin F, Pavo I, Stepan JJ (2014) Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 59:139\u2013147. https:\/\/doi.org\/10.1016\/j.bone.2013.11.011","journal-title":"Bone"},{"key":"354_CR58","doi-asserted-by":"publisher","first-page":"14004","DOI":"10.1074\/jbc.M114.628818","volume":"290","author":"A Maeda","year":"2015","unstructured":"Maeda A, Ono M, Holmbeck K, Li L, Kilts TM, Kram V, Noonan ML, Yoshioka Y, McNerny EM, Tantillo MA, Kohn DH, Lyons KM, Robey PG, Young MF (2015) WNT1-induced secreted protein-1 (WISP1), a novel regulator of bone turnover and WNT signaling. J Biol Chem 290:14004\u201314018. https:\/\/doi.org\/10.1074\/jbc.M114.628818","journal-title":"J Biol Chem"},{"key":"354_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1210\/edrv.21.2.0395","volume":"21","author":"SC Manolagas","year":"2000","unstructured":"Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115\u2013137. https:\/\/doi.org\/10.1210\/edrv.21.2.0395","journal-title":"Endocr Rev"},{"key":"354_CR60","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, Group AMGBLS (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831. https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"N Engl J Med"},{"key":"354_CR61","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"354_CR62","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP (2008) Open-label study to determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide I. early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785\u20133793. https:\/\/doi.org\/10.1210\/jc.2008-0353","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR63","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394\u2013402. https:\/\/doi.org\/10.1210\/jc.2010-1805","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR64","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, Investigators AS (2016) Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733. https:\/\/doi.org\/10.1001\/jama.2016.11136","journal-title":"JAMA"},{"key":"354_CR65","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1210\/jc.2002-021988","volume":"88","author":"BM Misof","year":"2003","unstructured":"Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150\u20131156. https:\/\/doi.org\/10.1210\/jc.2002-021988","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR66","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1469-7580.2006.00509.x","volume":"208","author":"S Mohsin","year":"2006","unstructured":"Mohsin S, O'Brien FJ, Lee TC (2006) Osteonal crack barriers in ovine compact bone. J Anat 208:81\u201389. https:\/\/doi.org\/10.1111\/j.1469-7580.2006.00509.x","journal-title":"J Anat"},{"key":"354_CR67","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","volume":"97","author":"CA Moreira","year":"2017","unstructured":"Moreira CA, Fitzpatrick LA, Wang Y, Recker RR (2017) Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone 97:314\u2013319. https:\/\/doi.org\/10.1016\/j.bone.2016.11.004","journal-title":"Bone"},{"key":"354_CR68","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106. https:\/\/doi.org\/10.1210\/jc.2011-3479","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR69","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"354_CR70","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/jbmr.2482","volume":"30","author":"P Nioi","year":"2015","unstructured":"Nioi P, Taylor S, Hu R, Pacheco E, He YD, Hamadeh H, Paszty C, Pyrah I, Ominsky MS, Boyce RW (2015) Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats. J Bone Miner Res 30:1457\u20131467. https:\/\/doi.org\/10.1002\/jbmr.2482","journal-title":"J Bone Miner Res"},{"key":"354_CR71","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30:1280\u20131289. https:\/\/doi.org\/10.1002\/jbmr.2480","journal-title":"J Bone Miner Res"},{"key":"354_CR72","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/jbmr.3036","volume":"32","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyd SK, Varela A, Jolette J, Felx M, Doyle N, Mellal N, Smith SY, Locher K, Buntich S, Pyrah I, Boyce RW (2017) Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res 32:788\u2013801. https:\/\/doi.org\/10.1002\/jbmr.3036","journal-title":"J Bone Miner Res"},{"key":"354_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"354_CR74","first-page":"273","volume":"4","author":"AM Parfitt","year":"1980","unstructured":"Parfitt AM (1980) Morphological basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 4:273\u2013287","journal-title":"Miner Electrolyte Metab"},{"issue":"Suppl 1","key":"354_CR75","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1007\/BF02406145","volume":"36","author":"AM Parfitt","year":"1984","unstructured":"Parfitt AM (1984) Age-related structural changes in trabecular and cortical bone: cellular mechanisms and biomechanical consequences. Calcif Tissue Int 36(Suppl 1):S123\u2013S128","journal-title":"Calcif Tissue Int"},{"key":"354_CR76","volume-title":"Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis","author":"AM Parfitt","year":"2008","unstructured":"Parfitt AM (2008) Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis. Academic Press, Cambridge"},{"key":"354_CR77","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1210\/jc.2004-2489","volume":"90","author":"EP Paschalis","year":"2005","unstructured":"Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005) Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 90:4644\u20134649. https:\/\/doi.org\/10.1210\/jc.2004-2489","journal-title":"J Clin Endocrinol Metab"},{"key":"354_CR78","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jmbbm.2015.08.012","volume":"52","author":"AA Poundarik","year":"2015","unstructured":"Poundarik AA, Wu PC, Evis Z, Sroga GE, Ural A, Rubin M, Vashishth D (2015) A direct role of collagen glycation in bone fracture. J Mech Behav Biomed Mater 52:120\u2013130. https:\/\/doi.org\/10.1016\/j.jmbbm.2015.08.012","journal-title":"J Mech Behav Biomed Mater"},{"key":"354_CR79","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nrendo.2015.71","volume":"11","author":"IR Reid","year":"2015","unstructured":"Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11:418\u2013428. https:\/\/doi.org\/10.1038\/nrendo.2015.71","journal-title":"Nat Rev Endocrinol"},{"key":"354_CR80","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1001\/archinte.168.20.2276","volume":"168","author":"IR Reid","year":"2008","unstructured":"Reid IR, Ames R, Mason B, Reid HE, Bacon CJ, Bolland MJ, Gamble GD, Grey A, Horne A (2008) Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 168:2276\u20132282. https:\/\/doi.org\/10.1001\/archinte.168.20.2276","journal-title":"Arch Intern Med"},{"key":"354_CR81","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/jor.1100060613","volume":"6","author":"CB Ruff","year":"1988","unstructured":"Ruff CB, Hayes WC (1988) Sex differences in age-related remodeling of the femur and tibia. J Orthop Res 6:886\u2013896. https:\/\/doi.org\/10.1002\/jor.1100060613","journal-title":"J Orthop Res"},{"key":"354_CR82","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759. https:\/\/doi.org\/10.1007\/s00198-007-0540-8","journal-title":"Osteoporos Int"},{"key":"354_CR83","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"354_CR84","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1056\/NEJMc1714810","volume":"378","author":"KG Saag","year":"2018","unstructured":"Saag KG, Petersen J, Grauer A (2018) Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 378:195\u2013196. https:\/\/doi.org\/10.1056\/NEJMc1714810","journal-title":"N Engl J Med"},{"key":"354_CR85","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00198-009-1066-z","volume":"21","author":"M Saito","year":"2010","unstructured":"Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195\u2013214. https:\/\/doi.org\/10.1007\/s00198-009-1066-z","journal-title":"Osteoporos Int"},{"key":"354_CR86","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00198-008-0585-3","volume":"19","author":"M Saito","year":"2008","unstructured":"Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K (2008) Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 19:1343\u20131354. https:\/\/doi.org\/10.1007\/s00198-008-0585-3","journal-title":"Osteoporos Int"},{"key":"354_CR87","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s00198-010-1454-4","volume":"22","author":"M Saito","year":"2011","unstructured":"Saito M, Marumo K, Kida Y, Ushiku C, Kato S, Takao-Kawabata R, Kuroda T (2011) Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos Int 22:2373\u20132383. https:\/\/doi.org\/10.1007\/s00198-010-1454-4","journal-title":"Osteoporos Int"},{"key":"354_CR88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1359\/jbmr.060915","volume":"22","author":"R Samadfam","year":"2007","unstructured":"Samadfam R, Xia Q, Goltzman D (2007) Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55\u201363. https:\/\/doi.org\/10.1359\/jbmr.060915","journal-title":"J Bone Miner Res"},{"key":"354_CR89","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMp038101","volume":"349","author":"E Seeman","year":"2003","unstructured":"Seeman E (2003) Periosteal bone formation--a neglected determinant of bone strength. N Engl J Med 349:320\u2013323. https:\/\/doi.org\/10.1056\/NEJMp038101","journal-title":"N Engl J Med"},{"key":"354_CR90","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD (2006) Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med 354:2250\u20132261. https:\/\/doi.org\/10.1056\/NEJMra053077","journal-title":"N Engl J Med"},{"key":"354_CR91","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/jbmr.2496","volume":"30","author":"E Seeman","year":"2015","unstructured":"Seeman E, Martin TJ (2015) Co-administration of antiresorptive and anabolic agents: a missed opportunity. J Bone Miner Res 30:753\u2013764. https:\/\/doi.org\/10.1002\/jbmr.2496","journal-title":"J Bone Miner Res"},{"key":"354_CR92","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41584-019-0172-3","volume":"15","author":"E Seeman","year":"2019","unstructured":"Seeman E, Martin TJ (2019) Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat Rev Rheumatol 15:225\u2013236. https:\/\/doi.org\/10.1038\/s41584-019-0172-3","journal-title":"Nat Rev Rheumatol"},{"key":"354_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00198-015-3374-9","volume":"27","author":"E Seeman","year":"2016","unstructured":"Seeman E, Nguyen TV (2016) Bone remodeling markers: so easy to measure, so difficult to interpret. Osteoporos Int 27:33\u201335. https:\/\/doi.org\/10.1007\/s00198-015-3374-9","journal-title":"Osteoporos Int"},{"key":"354_CR94","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/jbmr.2309","volume":"29","author":"Z Seref-Ferlengez","year":"2014","unstructured":"Seref-Ferlengez Z, Basta-Pljakic J, Kennedy OD, Philemon CJ, Schaffler MB (2014) Structural and mechanical repair of diffuse damage in cortical bone in vivo. J Bone Miner Res 29:2537\u20132544. https:\/\/doi.org\/10.1002\/jbmr.2309","journal-title":"J Bone Miner Res"},{"key":"354_CR95","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/BF00296285","volume":"50","author":"V Shen","year":"1992","unstructured":"Shen V, Dempster DW, Mellish RW, Birchman R, Horbert W, Lindsay R (1992) Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17 beta-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif Tissue Int 50:214\u2013220","journal-title":"Calcif Tissue Int"},{"key":"354_CR96","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","volume":"23","author":"SL Silverman","year":"2012","unstructured":"Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study Group (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351\u2013363. https:\/\/doi.org\/10.1007\/s00198-011-1691-1","journal-title":"Osteoporos Int"},{"key":"354_CR97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11914-012-0103-6","volume":"10","author":"GE Sroga","year":"2012","unstructured":"Sroga GE, Vashishth D (2012) Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr Osteoporos Rep 10:141\u2013150. https:\/\/doi.org\/10.1007\/s11914-012-0103-6","journal-title":"Curr Osteoporos Rep"},{"key":"354_CR98","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.bone.2006.12.056","volume":"40","author":"SY Tang","year":"2007","unstructured":"Tang SY, Zeenath U, Vashishth D (2007) Effects of non-enzymatic glycation on cancellous bone fragility. Bone 40:1144\u20131151. https:\/\/doi.org\/10.1016\/j.bone.2006.12.056","journal-title":"Bone"},{"key":"354_CR99","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/jbmr.3640","volume":"34","author":"G Tatangelo","year":"2019","unstructured":"Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgstrom F, Nicholson GC, Shore-Lorenti C, Stuart AL, Iuliano-Burns S, Seeman E, Prince R, March L, Cross M, Winzenberg T, Laslett LL, Duque G, Ebeling PR, Sanders KM (2019) The cost of osteoporosis, osteopenia, and associated fractures in Australia in 2017. J Bone Miner Res 34:616\u2013625. https:\/\/doi.org\/10.1002\/jbmr.3640","journal-title":"J Bone Miner Res"},{"key":"354_CR100","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","volume":"84","author":"S Taylor","year":"2016","unstructured":"Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, Brown DL, Aguirre JI, Wronski TJ, Buntich S, Afshari CA, Pyrah I, Nioi P, Boyce RW (2016) Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone 84:148\u2013159. https:\/\/doi.org\/10.1016\/j.bone.2015.12.013","journal-title":"Bone"},{"key":"354_CR101","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ab.2017.02.011","volume":"525","author":"CJ Thomas","year":"2017","unstructured":"Thomas CJ, Cleland TP, Zhang S, Gundberg CM, Vashishth D (2017) Identification and characterization of glycation adducts on osteocalcin. Anal Biochem 525:46\u201353. https:\/\/doi.org\/10.1016\/j.ab.2017.02.011","journal-title":"Anal Biochem"},{"key":"354_CR102","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/ar.1092020403","volume":"202","author":"PT Tran Van","year":"1982","unstructured":"Tran Van PT, Vignery A, Baron R (1982) Cellular kinetics of the bone remodeling sequence in the rat. Anat Rec 202:445\u2013451. https:\/\/doi.org\/10.1002\/ar.1092020403","journal-title":"Anat Rec"},{"key":"354_CR103","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(13)60856-9","journal-title":"Lancet"},{"key":"354_CR104","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jbmr.2315","volume":"30","author":"JN Tsai","year":"2015","unstructured":"Tsai JN, Uihlein AV, Burnett-Bowie SA, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ (2015) Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study. J Bone Miner Res 30:39\u201345. https:\/\/doi.org\/10.1002\/jbmr.2315","journal-title":"J Bone Miner Res"},{"key":"354_CR1000","doi-asserted-by":"publisher","unstructured":"Tsai JN, Nishiyama KK, Lin D, Yuan A, Lee H, Bouxsein ML, Leder BZ (2017) Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-Switch HR-pQCT study. J Bone Miner Res 32:2001\u20132009. https:\/\/doi.org\/10.1002\/jbmr.3198","DOI":"10.1002\/jbmr.3198"},{"key":"354_CR105","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.3003","volume":"32","author":"A Varela","year":"2017","unstructured":"Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G (2017) One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res 32:24\u201333. https:\/\/doi.org\/10.1002\/jbmr.3003","journal-title":"J Bone Miner Res"},{"key":"354_CR106","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11914-007-0004-2","volume":"5","author":"D Vashishth","year":"2007","unstructured":"Vashishth D (2007) The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 5:62\u201366. https:\/\/doi.org\/10.1007\/s11914-007-0004-2","journal-title":"Curr Osteoporos Rep"},{"key":"354_CR107","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/joim.12718","volume":"283","author":"AG Veldhuis-Vlug","year":"2018","unstructured":"Veldhuis-Vlug AG, Rosen CJ (2018) Clinical implications of bone marrow adiposity. J Intern Med 283:121\u2013139. https:\/\/doi.org\/10.1111\/joim.12718","journal-title":"J Intern Med"},{"key":"354_CR108","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1210\/endo.132.2.8425497","volume":"132","author":"TJ Wronski","year":"1993","unstructured":"Wronski TJ, Yen CF, Qi H, Dann LM (1993) Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132:823\u2013831. https:\/\/doi.org\/10.1210\/endo.132.2.8425497","journal-title":"Endocrinology"},{"key":"354_CR109","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.2419","volume":"30","author":"R Zebaze","year":"2015","unstructured":"Zebaze R, Seeman E (2015) Cortical bone: a challenging geography. J Bone Miner Res 30:24\u201329. https:\/\/doi.org\/10.1002\/jbmr.2419","journal-title":"J Bone Miner Res"},{"key":"354_CR110","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","volume":"375","author":"RM Zebaze","year":"2010","unstructured":"Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E (2010) Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375:1729\u20131736. https:\/\/doi.org\/10.1016\/S0140-6736(10)60320-0","journal-title":"Lancet"},{"key":"354_CR111","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bone.2013.01.007","volume":"54","author":"R Zebaze","year":"2013","unstructured":"Zebaze R, Ghasem-Zadeh A, Mbala A, Seeman E (2013) A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images. Bone 54:8\u201320. https:\/\/doi.org\/10.1016\/j.bone.2013.01.007","journal-title":"Bone"}],"container-title":["Handbook of Experimental Pharmacology","Bone Regulators and Osteoporosis Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2020_354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T20:06:43Z","timestamp":1606594003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2020_354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030573775","9783030573782"],"references-count":112,"URL":"https:\/\/doi.org\/10.1007\/164_2020_354","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"31 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}